Table 2.

Concentrations of homeostatic model assessment (HOMA-IR)—Eq. (1), triglycerides (TG) and Castelli’s risk index II (CRI II)—Eq. (3) in the participants’ blood in the aerobic group (EG1), aerobic-resistance group (EG2), and control group (CG).

	Group	Week 1, baseline	Week 6, intervention	Week 12, intervention	Week 16, follow up	Between measurements comparison p-value and ES
		X® ± SD	X® ± SD	X® ± SD	X® ± SD	Test ANOVA (ES)	d 6–1 (ES)	d 12–1 (ES)	d 16–1 (ES)
HOMA-IR	EG1	4.53 ± 3.51	3.88 ± 4.66	4.31 ± 3.57	3.58 ± 3.45	0.29 (0.01)	0.39 (0.29)	0.10 (0.60)	0.09 (0.60)
	EG2	3.91 ± 2.08	4.91 ± 3.16	2.73 ± 1.28	2.26 ± 0.90	0.03 (0.14)	0.06 (0.67)	0.28 (0.37)	0.04 (0.77)
	CG	6.03 ± 5.05	5.26 ± 2.09	6.18 ± 4.77	5.60 ± 5.82	0.79 (0.01)	0.81 (0.08)	0.31 (0.36)	0.97 (0.01)
	p-value between groups	0.28	0.57	0.04*	0.15
TG (mmol/L)	EG1	1.66 ± 0.81	1.60 ± 0.87	1.68 ± 0.76	1.50 ± 0.66	0.38 (0.01)	0.80 (0.08)	0.21 (0.43)	0.39 (0.29)
	EG2	1.90 ± 1.22	1.96 ± 1.15	1.80 ± 0.67	1.71 ± 0.62	0.25 (0.04)	0.11 (0.56)	0.13 (0.53)	0.57 (0.19)
	CG	2.47 ± 1.91	2.74 ± 2.83	3.56 ± 4.13	2.39 ± 2.07	0.14 (0.04)	0.06 (0.72)	0.21 (0.46)	0.08 (0.66)
	p-value between groups	0.29	0.28	0.11	0.22
CRI II	EG1	2.80 ± 1.38	2.51 ± 0.98	2.40 ± 1.31	2.78 ± 1.24	0.02 (0.02)	0.99 (0.00)	0.01 (0.97)	0.95 (0.02)
	EG2	3.04 ± 0.91	2.73 ± 0.78	2.79 ± 0.83	2.92 ± 0.83	0.08 (0.03)	0.04 (0.73)	0.10 (0.58)	0.14 (0.51)
	CG	3.23 ± 0.83	3.18 ± 1.15	2.78 ± 0.57	3.24 ± 1.06	0.69 (0.02)	0.18 (0.58)	0.38 (0.36)	0.46 (0.30)
	p-value between groups	0.58	0.32	0.53	0.57

*Post-hoc: EG2-CG, p = 0.04; d 6–1, d 12–1, d 16–1 – differences in results obtained after 6 and 12 weeks of interventions, respectively, and after 4 weeks of follow-up in relation to measurements taken before interventions, X® mean, SD standard deviation, p < 0.05 – statistically significant difference, ES effect size.